NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough NVAX stock surges amid biotech stock rally following Moderna and Merck cancer breakthrough. Barchart · Aug 21
What Trump’s push for fewer vaccines could mean for US children The U.S. Department of Health and Human Services is seeking public comments on vaccine recommendations. This review follows President Donald Trump's directive to examine childhood immunization schedules. The department is exploring new ways to classify and communicate vaccine guidance. Feedback is being gathered on shared decision-making and public trust concerns.… The Economic Times · Aug 21
HHS seeks input on kids vaccination changes called for by Trump The Department of Health and Human Services on Friday outlined potential changes to the childhood vaccine schedule, suggesting kids shots should be spread farther apart in contrast to recommendations from pediatric groups. The request for information fulfills directives outlined in President Donald Trump’s executive order from Aug. 10 that seeks to stagger vaccine… Roll Call · Aug 21
Australian Data Put the Maternal RSV Vaccine at 78 Percent Effective Against Infant Lung Infection Admissions A JAMA Pediatrics study of 1,012 hospitalized infants found maternal RSV vaccine effectiveness to be 77.8% against lung infection admissions through six months. Medical Daily · Aug 21
Why millions of people around the world will contract measles in 2026 The World Health Organization estimates that in 2026 nearly 11 million people will contract the virus that causes measles. Most of these cases will occur in Africa and Asia, but many countries in the Americas and Europe are reporting outbreaks affecting hundreds or thousands of people. The Conversation · Aug 21
New CDC Chief Tells Staff She Will Challenge Kennedy Privately While Funded Programs Sit Without People In her first all-hands meeting, CDC Director Erica Schwartz acknowledged understaffed programs and burnout and said she would disagree with Kennedy privately. Medical Daily · Aug 21
Moderna’s 177% Surge Has Investors Asking What Comes Next Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze. MarketBeat · Aug 21
Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches. International Business Times · Aug 21
Moderna's Vaccine Breakthrough Supported by AI: Musk Praises mRNA Despite 'Obvious Misuse During COVID' Moderna and Merck's personalised mRNA vaccine shows promising Phase 3 results in melanoma treatment, potentially revolutionising cancer care with tailored immunotherapy. International Business Times UK · Aug 21
Horseshoe Crab Blood Powers Every Vaccine and Injection You Have Ever Been Given The blue blood that guards every hospital on EarthHorseshoe crab blood is blue. Not metaphorically, literally blue, because it uses copper-based hemocyanin to carry oxygen instead of the iron-based hemoglobin that makes human blood red. But the colour is not why the biomedical industry harvests roughly 600,000 horseshoe crabs every… Times Life · Aug 21
Vaccinated Measles Patients Occasionally Infect Others, and Contact Tracers Are Now Being Urged Not to Rule Them Out A review of 33 reports found that 7.9% of vaccinated measles patients transmitted the virus. Most had a milder illness. What does it mean for families? Medical Daily · Aug 21
The Guardian view on Trump’s MMR executive order: endangering the children he claims to care about Editorial: The president’s empty advice that children should receive separate jabs against measles, mumps and rubella will only lead to less take-up by parents The Guardian - UK · Aug 20
Five years on from first vaccine, fight against malaria sees progress in Africa On World Mosquito Day, attention remains focused on the devastating impact of the disease in Africa. The continent accounts for 95 per cent of malaria-related deaths worldwide. Five years after the roll-out of the first malaria vaccine, it is beginning to deliver measurable results – although significant challenges remain. Radio France Internationale · Aug 20
Republicans revive false miscarriage statistic, twist Fauci’s texts about COVID-19 shots By Kate Yandell ANALYSIS — Studies have shown no connection between COVID-19 vaccination during pregnancy and increased risk of miscarriage. Despite this, Republican Sens. Rand Paul and Ron Johnson resurrected a long-debunked claim of an astronomical rate of miscarriage after vaccination while also accusing Dr. Anthony Fauci of deceiving the… Roll Call · Aug 20
Euronews · Aug 20 DR Congo to receive 70,000 doses of Ebola vaccine used in past outbreaks, WHO says The International Coordinating Group on Vaccine Provision, which includes the WHO and other partners, said the doses will be released immediately following a request from DR Congo’s government.
Medical Daily · Aug 20 Flu and COVID Vaccines Are Expected This Fall with Insurer Coverage Despite a Stalled Federal Advisory Committee Infectious disease specialists say updated flu and COVID vaccines will be available and covered this fall even though the federal advisory panel has not acted.
The Independent UK · Aug 20 Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks The World Health Organization says Congo will receive 70,000 doses of the Ervebo vaccine
The Independent UK · Aug 20 How does Moderna’s new melanoma vaccine work – and could it treat other cancers? Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK
International Business Times UK · Aug 20 Short Sellers Just Lost $5B on the Wrong Pharma Bet: Cancer Vaccine Sends Stock Soaring 177% Moderna's shares surged 177% after positive cancer vaccine trial results, causing $5 billion losses for short sellers. This marks a potential shift beyond its COVID-19 vaccine business.
International Business Times UK · Aug 20 Moderna's Personalised Cancer Vaccine Clears Phase 3: How Soon Could Patients Receive It? Moderna and Merck's personalised cancer vaccine shows positive Phase 3 results, reducing melanoma recurrence risk. Regulatory approval is pending, with potential market availability by 2027.
The Economic Times · Aug 20 Moderna, Merck breakthrough could usher in wave of cancer vaccines Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are…
Benzinga · Aug 20 Trump’s FDA Pick Heidi Overton Faces Republican Resistance as Bill Cassidy Calls Vaccine Order Role ‘Almost Disqualifying’ President Donald Trump’s choice of Dr. Heidi Overton to lead the Food and Drug Administration faced Republican resistance Wednesday as Senate Health Committee Chair Bill Cassidy (R-La.) said her role in the administration’s vaccine order was "almost disqualifying."
Medical Daily · Aug 20 Two Grant County Cases Push the Southwestern Wisconsin Measles Outbreak to Thirty Six Confirmed and Three Probable Wisconsin health officials confirmed measles in Grant County, expanding a southwestern outbreak the state says is now spreading locally.
Medical Daily · Aug 19 A Pooled 24 Country Analysis Ties Rotavirus Vaccination to Fewer Deaths Among Children Hospitalized with Diarrhea A Lancet analysis pooling case-control studies across 24 countries links rotavirus vaccination to lower mortality from rotavirus gastroenteritis.
Benzinga · Aug 19 Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boost.